Table 1.
Organism | No. of isolates | MIC90b | MIC rangeb | % Susceptiblec | References |
---|---|---|---|---|---|
Staphylococcus aureus | 8765 | 0.5 | ≤0.016–1 | 99.4 | (Sader et al 2005) |
MSSA | 813 | 0.12 | 0.015–0.5 | 100 | (Waites et al 2006) |
MRSA | 879 | 0.25 | 0.03–0.5 | 100 | (Waites et al 2006) |
VISA | 19 | 0.5 | 0.06–1 | NAd | (Petersen et al 2002) |
Staphylococci, coagulase-negative (CoNS) | 3570 | 0.5 | ≤0.016–2 | 97.5 | (Sader et al 2005) |
CoNS, methicillin susceptible | 71 | 0.5 | 0.03–1 | NAd | (Fritsche, Sader et al 2005) |
CoNS, methicillin resistant | 189 | 0.5 | ≤0.12–2 | NAd | (Fritsche, Sader et al 2005) |
S. pneumoniae | 605 | ≤0.12 | ≤0.12–1 | --e | (Sader et al 2005) |
S. pneumoniae, penicillin susceptible | 279 | 0.5 | NAd | NAd | (Hoban et al 2005) |
S. pneumoniae, penicillin-resistant | 54 | 0.25 | NAd | NAd | (Hoban et al 2005) |
Streptococci, β-hemolytic | 769 | ≤0.12 | ≤0.12–0.5 | 99.7 | (Sader et al 2005) |
Streptococci, viridans group | 378 | ≤0.12 | ≤0.12–0.05 | 98.1 | (Sader et al 2005) |
Enterococci spp. | 3258 | 0.25 | ≤0.016–2 | 92.7 | (Sader et al 2005) |
Enterococcus spp.-vancomycin susceptible | 466 | 0.5 | ≤0.12–1 | NAd | (Fritsche, Sader et al 2005) |
Enterococcus spp.-vancomycin resistant | 39 | 0.25 | 0.03–0.5 | NAd | (Fritsche, Sader et al 2005) |
Nocardia spp. | 51 | 4 | ≤0.06–8 | NAd | (Cercenado et al 2007) |
Escherichia coli | 3217 | 0.25 | 0.03–4 | >99.9 | (Sader et al 2005) |
ESBL-producing E.coli | 115 | 0.38 | 0.047–0.75 | NAd | (Sorlozano et al 2006) |
Klebsiella pneumonia | 1334 | 2 | ≤0.008–8 | 95 | (Waites et al 2006) |
ESBL-producing | 126 | 2 | 0.12–8 | 92.1 | (Waites et al 2006) |
K. pneumoniae | |||||
Klebsiella oxytoca | 248 | 1 | 0.06–4 | 98.8 | (Waites et al 2006) |
Enterobacter aerogenes | 419 | 1 | 0.06–8 | 95.7 | (Waites et al 2006) |
Enterobacter cloacae | 1089 | 2 | ≤0.008–8 | 93 | (Waites et al 2006) |
Haemophilus influenzae | 336 | 0.25 | NAd | --e | (Hoban et al 2005) |
H. influenzae, β-lactamase positive | 93 | 0.25 | NAd | --e | (Hoban et al 2005) |
Moraxella catarrhalis | 54 | 0.5 | NAd | --e | (Gales et al 2005) |
Serratia marscens | 658 | 1 | 0.012–8 | 97 | (Waites et al 2006) |
Citrobacter spp. | 252 | 0.5 | NAd | 86.9 | (Fritsche, Strabala et al 2005) |
Acinetobacter baumannii | 851 | 1 | 0.03-8 | --e | (Waites et al 2006) |
Pseudomonas aeruginosa | 1338 | ≥32 | ≤0.008–≥32 | --e | (Waites et al 2006) |
Stenotrophomonas maltophilia | 203 | 2 | 0.12–8 | --e | (Sader et al 2005) |
Burkholderia cepacia | 21 | 16 | 0.25–32 | --e | (Cheng et al 2005) |
Campylobacter jejuni | 108 | 4 | 0.12–16 | --e | (Rodriguez-Avial et al 2006) |
Campylobacter coli | 8 | 16 | 0.5–16 | --e | (Rodriguez-Avial et al 2006) |
Proteus mirabilis | 320 | 4 | 0.25–16 | 46.9 | (Sader et al 2005) |
Bacteroides fragilis | 2721 | 8 | 0.06–32 | 94.9 | (Snydman et al 2007) |
Bacteroides fragilis group | 5225 | 8 | 0.06–64 | 95.7 | (Snydman et al 2007) |
B. distasonis | 274 | 8 | 0.25–32 | 97.9 | (Snydman et al 2007) |
B. ovatus | 545 | 8 | 0.125–16 | 96.7 | (Snydman et al 2007) |
B. thetaiotaomicron | 978 | 8 | 0.25–32 | 96.4 | (Snydman et al 2007) |
B. vulgatus | 306 | 4 | 0.25–16 | 98.4 | (Snydman et al 2007) |
C. perfringens | 51 | 1.0 | ≤0.06–2 | NAd | (Bradford et al 2005) |
Clostridium difficile | 12 | 0.06 | 0.06 | NAd | (Goldstein et al 2006) |
Fusobacterium varium | 13 | 0.25 | 0.06–0.25 | NAd | (Goldstein et al 2006) |
Lactobacillus spp. | 15 | 0.5 | 0.06–1 | NAd | (Goldstein et al 2006) |
Adapted with permission from (Townsend ML et al 2006. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract, 60:1662–72. Blackwell Publishing.)
MIC = minimum inhibitory concentration.
According to CLSI criteria.
NA = not available.
No CLSI criteria available.